JNCE - ジョンス・セラピュ―ティクス （Jounce Therapeutics Inc.）JNCEのニュース
Board Member at Jounce Therapeutics Exercises Options Worth $236K 2023/05/04 15:03:55 Benzinga
Gayle Barbara Duncan , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Duncan, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 125,761 shares of JNCE stock with an exercise price of $5.68. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Duncan''s 125,761 shares worth $236,430. Now trade stocks online … Full story available on Benzinga.com
Jounce Therapeutics Board Member Acquires 104,363 Shares After Exercising Company Stock Options 2023/05/04 15:03:48 Benzinga
Luis Diaz , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Diaz, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 104,363 shares of JNCE stock with an exercise price of $8.05. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Diaz''s 104,363 shares worth $196,202. Now trade stocks online … Full story available on Benzinga.com
Director at Jounce Therapeutics Exercises Options Worth $111K 2023/05/04 15:03:40 Benzinga
Luisa SalterCid , Director at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that SalterCid, Director at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 59,250 shares of JNCE stock with an exercise price of $8.46. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes SalterCid''s 59,250 shares worth $111,390. Now trade stocks online commission free … Full story available on Benzinga.com
Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options 2023/05/04 15:03:33 Benzinga
Jigar Raythatha , Director at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Raythatha, Director at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 51,400 shares of JNCE stock with an exercise price of $5.04. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Raythatha''s 51,400 shares worth $96,632. Now trade stocks online commission … Full story available on Benzinga.com
Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options 2023/05/04 15:03:23 Benzinga
CA RICHARD MURRAY , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that MURRAY, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 1,883,269 shares of JNCE stock with an exercise price of $6.53. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes MURRAY''s 1,883,269 shares worth $3,540,545. Now trade stocks online … Full story available on Benzinga.com
Powerful stocks to Increase Your Investments: Meta Materials Inc. (NASDAQ:MMAT), Jounce Therapeutics, Inc. (NASDAQ:JNCE) 2023/04/11 04:53:52 Stock Equity
MMAT has seen its SMA50 which is now -35.66%. In looking the SMA 200 we see that the stock has seen a -57.60%. JNCE has seen its SMA50 which is … The post Powerful stocks to Increase Your Investments: Meta Materials Inc. (NASDAQ:MMAT), Jounce Therapeutics, Inc. (NASDAQ:JNCE) appeared first on Stocks Equity .
Jounce Therapeutics and Redx Pharma Terminate Proposed Merger 2023/04/03 09:19:02 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-and-redx-pharma-terminate-proposed-merger-432SI-3047391
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc 2023/04/03 06:00:00 GlobeNewswire
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Baird maintains Jounce Therapeutics at Neutral 2023/03/28 11:52:36 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-inc-receives-investment-bank-analyst-rating-update-3042293
Jounce Therapeutics PT Lowered to $2 at Baird 2023/03/28 10:45:04 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-pt-lowered-to-2-at-baird-432SI-3042156
Jounce Therapeutics PT Lowered to $16 at Raymond James 2022/08/30 18:01:02 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-pt-lowered-to-16-at-raymond-james-432SI-2882806
JNCE stock drops as lung cancer therapy fails in mid-stage trial (NASDAQ:JNCE) 2022/08/30 12:39:41 Seeking Alpha
Cambridge, Massachusetts-based Jounce Therapeutics, Inc
Boom Or Bust: What Are Jounce Therapeutics Inc.’s (NASDAQ:JNCE) Future Prospects? 2022/08/20 18:00:00 Marketing Sentinel
Jounce Therapeutics Inc. (NASDAQ:JNCE)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 1.22. At the close of trading, the stock’s price was $4.65, to imply a decrease of 0.00% or $0.0 in intraday trading. The JNCE share’s 52-week high remains $9.81, putting it -110.97% down since that … Boom Or Bust: What Are Jounce Therapeutics Inc.’s (NASDAQ:JNCE) Future Prospects? Read More »
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call Transcript 2022/08/05 21:51:02 Seeking Alpha
Jounce Therapeutics, Inc. (NASDAQ:NASDAQ:JNCE) Q2 2022 Earnings Conference Call August 04, 2022 08:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray…